Viatris stock: Oppenheimer lifts target to 26 dollars after Pacira deal
Published on 11/19/2026 at 14:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst raises target after acquisition
- Oppenheimer lifted its Viatris target to 26 dollars from 25 dollars and kept an Outperform rating.
- The firm now forecasts 2027 revenue of 15.8 billion dollars and EBITDA of 5 billion dollars.
- Pacira adds two marketed pain products and a commercial team that can support Viatris' planned meloxicam launch.
Oppenheimer raised its price target for Viatris to 26 dollars from 25 dollars on Wednesday, November 18, while keeping an Outperform rating. Markets Insider reported that the analyst added Pacira to the Viatris model after the transaction closed.
The revised view assigns Pacira's two marketed pain products and commercial team a role in Viatris' growth plans. The team could also support the planned launch of fast-acting meloxicam, according to the report.
Forecasts move higher for 2027
Oppenheimer now forecasts 2027 revenue of 15.8 billion dollars and EBITDA of 5 billion dollars. The higher target reflects the firm's updated model after the Pacira acquisition, while the retained Outperform rating signals a positive analyst stance.
Viatris stock traded at 18.42 euros on Lang & Schwarz at 14:01 CET on Thursday, November 19, 2026.
Viatris company facts
- Company: Viatris Inc.
- ISIN: US92556V1061
- Ticker: VTRS
- Home exchange: Nasdaq
- Lang & Schwarz quote: 18.42 euros on November 19, 2026 at 14:01 CET
The U.S. market backdrop is tracked through the S&P 500.
